Spero Therapeutics, Inc. (SPRO) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
SPRO currently has 57.3M outstanding shares. with minimal authorized share overhang for future dilution. The company has minimally diluted shareholders by 9.32% over the past 2 years.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 13, 2026 |
10-Q filing | 57.3M shares outstanding |
57M | 0 |
| Mar 26, 2026 |
10-K filing | 59.0M shares outstanding |
59M | 0 |
| Nov 13, 2025 |
10-Q filing | 56.3M shares outstanding |
56M | 0 |
| Aug 12, 2025 |
10-Q filing | 56.0M shares outstanding |
56M | 0 |
| May 13, 2025 |
10-Q filing | 55.4M shares outstanding |
55M | 0 |
| Mar 27, 2025 |
10-K filing | 54.0M shares outstanding |
54M | 0 |
| Nov 14, 2024 |
10-Q filing | 54.1M shares outstanding |
54M | 0 |
| Aug 05, 2024 |
10-Q filing | 54.0M shares outstanding |
54M | 0 |
| May 15, 2024 |
10-Q filing | 53.5M shares outstanding |
54M | 0 |
| Mar 15, 2024 |
S-3 filing: Spero Therapeutics, Inc. intends to offer up to $300,000,000 of any combination of common stock, preferred stock, or debt securities. |
53M | 0 |
| Mar 13, 2024 |
10-K filing | 53.0M shares outstanding |
53M | 0 |
| Nov 13, 2023 |
10-Q filing | 52.7M shares outstanding |
53M | 0 |
| Aug 10, 2023 |
10-Q filing | 52.6M shares outstanding |
53M | 0 |
| May 11, 2023 |
10-Q filing | 52.5M shares outstanding |
53M | 0 |
| Mar 30, 2023 |
10-K filing | 52.6M shares outstanding |
53M | 0 |
| Nov 14, 2022 |
10-Q filing | 51.8M shares outstanding |
52M | 0 |
| Aug 10, 2022 |
10-Q filing | 33.0M shares outstanding |
33M | 0 |
| May 16, 2022 |
10-Q filing | 32.8M shares outstanding |
33M | 0 |
| Mar 31, 2022 |
10-K filing | 32.8M shares outstanding |
33M | 0 |
| Nov 10, 2021 |
10-Q filing | 32.3M shares outstanding |
32M | 0 |
| Aug 05, 2021 |
10-Q filing | 32.1M shares outstanding |
32M | 0 |
| May 06, 2021 |
10-Q filing | 29.7M shares outstanding |
30M | 0 |
| Mar 11, 2021 |
10-K filing | 29.5M shares outstanding |
30M | 0 |
| Mar 11, 2021 |
S-3 filing: Spero Therapeutics, Inc. is offering up to $300,000,000 of any combination of common stock, preferred stock, and debt securities from time to time at prices and on terms to be determined at or prior to the time of the offering. |
29M | 0 |
| Nov 05, 2020 |
10-Q filing | 27.2M shares outstanding |
27M | 0 |
| Aug 06, 2020 |
10-Q filing | 21.2M shares outstanding |
21M | 0 |
| May 08, 2020 |
10-Q filing | 20.6M shares outstanding |
21M | 0 |
| Mar 16, 2020 |
10-K filing | 20.3M shares outstanding |
20M | 0 |